Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines.
Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines.
复制标题
全细胞癌症疫苗：从自体到同种异体肿瘤和基于树突状细胞的疫苗。
DOI：
10.1007/s00262-008-0536-z
复制
发表时间：
2008-10
影响因子：
5.8
通讯作者：
Scheper, Rik J.
中科院分区：
文献类型：
--
作者：
de Gruijl, Tanja D.;van den Eertwegh, Alfons J. M.;Pinedo, Herbert M.;Scheper, Rik J.
肿瘤疫苗接种领域目前正在经历重点转移，从个体化定制疫苗到更普遍适用的疫苗制剂。虽然主要由财务和后勤考虑预测，源于越来越多的认识，临床开发的大规模应用只能通过支持主要制药公司，这些新的方法也支持越来越多的知识的复杂性和细节的抗原呈递和效应T细胞活化。在这里，将讨论从个体化自体设置到更广泛适用的同种异体方法的全细胞肿瘤和树突状细胞（DC）疫苗的开发，这反映了过去二十年在荷兰阿姆斯特丹的vrije universiteit医学中心（VUmc）的实验室和诊所进行的转化研究。
The field of tumor vaccination is currently undergoing a shift in focus, from individualized tailor-made vaccines to more generally applicable vaccine formulations. Although primarily predicated by financial and logistic considerations, stemming from a growing awareness that clinical development for wide-scale application can only be achieved through backing from major pharmaceutical companies, these new approaches are also supported by a growing knowledge of the intricacies and minutiae of antigen presentation and effector T-cell activation. Here, the development of whole-cell tumor and dendritic cell (DC)-based vaccines from an individualized autologous set-up to a more widely applicable allogeneic approach will be discussed as reflected by translational studies carried out over the past two decades at our laboratories and clinics in the vrije universiteit medical center (VUmc) in Amsterdam, The Netherlands.
登录
查看更多内容
影响因子：
4.4
作者：
de Gruijl, TD;Luykx-de Bakker, SA;Gerritsen, WR
通讯作者：
Gerritsen, WR
影响因子：
50.5
作者：
Baars, A;Claessen, AME;Pinedo, HM
通讯作者：
Pinedo, HM
影响因子：
45.3
作者：
Berd, D;Sato, T;Mastrangelo, MJ
通讯作者：
Mastrangelo, MJ
影响因子：
45.3
作者：
Harris, JE;Ryan, L;Hanna, MG
通讯作者：
Hanna, MG
影响因子：
5.5
作者：
Hanna, MG;Hoover, HC;Pinedo, HM
通讯作者：
Pinedo, HM